Kamada Ltd
Research Kamada Ltd (KMDA) on Bullrun: valuation model: 1.1% overvalued, market cap USD 466.17M, P/E 21.2, dividend yield 5.4%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerKMDA
- ExchangeNASDAQ
- CountryIsrael
- SectorHealthcare
- IndustryDrug Manufacturers-Specialty & Generic
- CurrencyUSD
- Valuation signal1.1% overvalued
- Market capUSD 466.17M
- P/E21.2
- Dividend yield5.4%
- Financial periodQ2 2026
- RevenueUSD 54.92M
- Net incomeUSD 9.26M
- Free cash flowUSD 15.96M
- Gross margin40.9%
Valuation Snapshot
Bullrun's latest valuation model marks Kamada Ltd as 1.1% overvalued; latest market cap is USD 466.17M; P/E is 21.2; dividend yield is 5.4%.
Peer valuation comparison
Latest P/E is 21.17x versus a Healthcare sector median of 24.6x (13.9% below).
Latest dividend yield is 5.36% versus a Healthcare sector median of 1.84% (191.3% above).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 180.46M | USD 20.20M | USD 15.64M | 42.3% | 0.35 | USD 75.47M | USD 11.56M | USD 269.07M |
| FY2024 | USD 160.95M | USD 14.46M | USD 36.85M | 43.5% | 0.25 | USD 78.44M | USD 11.06M | USD 259.46M |
| FY2023 | USD 142.52M | USD 8.28M | -USD 1.54M | 38.9% | 0.15 | USD 55.64M | USD 8.82M | USD 244.02M |
| FY2022 | USD 129.34M | -USD 2.32M | USD 24.80M | 36.1% | -0.05 | USD 34.26M | USD 20.60M | USD 176.02M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-09 | USD 466.17M | 21.2 | 5.2% | 0.42 |
| 2025 | 2025-12-31 | USD 407.26M | 20.2 | 2.8% | 0.2 |
| 2024 | 2024-12-31 | USD 350.21M | 24.4 | n/a | n/a |
| 2023 | 2023-12-29 | USD 351.75M | 47.1 | n/a | n/a |
| 2022 | 2022-12-30 | USD 179.65M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 294.78M | n/a | n/a | n/a |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0.42 USD, yield 5.4%.
| Year | Dividends/share |
|---|---|
| FY2025 | 0.2 USD |
About Kamada Ltd
Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its products include KAMRAB/KEDRAB indicated as prophylaxis of rabies; CYTOGAM for prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis;
Related stock research
Other Healthcare stocks
Frequently asked questions
Is Kamada Ltd overvalued or undervalued?
Bullrun's valuation model currently marks Kamada Ltd as 1.1% overvalued.
What is Kamada Ltd's market cap?
Kamada Ltd's market capitalization is USD 466.17M.
What is Kamada Ltd's P/E ratio?
Kamada Ltd's price-to-earnings (P/E) ratio is 21.2.
Does Kamada Ltd pay a dividend?
Kamada Ltd has a dividend yield of 5.4%.
What does Kamada Ltd do?
Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its products include KAMRAB/KEDRAB indicated as prophylaxis of rabies; CYTOGAM for prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns;.